Predicting recurrence risk after neoadjuvant therapy in breast cancer: a single-center retrospective cohort study integrating residual cancer burden and immune microenvironment features
Residual cancer burden (RCB) after neoadjuvant therapy (NAT) provides prognostic information, but its combination with immune microenvironment features for recurrence prediction remains underexplored. This single-center retrospective cohort study included 420 consecutive patients with breast cancer who under...